Avalo Therapeutics Inc
NASDAQ:AVTX
Avalo Therapeutics Inc
Interest Income Expense
Avalo Therapeutics Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Avalo Therapeutics Inc
NASDAQ:AVTX
|
Interest Income Expense
-$82.3m
|
CAGR 3-Years
-258%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$663m
|
CAGR 3-Years
38%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$630.1m
|
CAGR 3-Years
93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Avalo Therapeutics Inc's Interest Income Expense?
Interest Income Expense
-82.3m
USD
Based on the financial report for Mar 31, 2024, Avalo Therapeutics Inc's Interest Income Expense amounts to -82.3m USD.
What is Avalo Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-258%
Over the last year, the Interest Income Expense growth was -1 893%. The average annual Interest Income Expense growth rates for Avalo Therapeutics Inc have been -258% over the past three years .